Abstract
AIM--To examine lymphocyte subsets in patients with myelodysplastic syndromes (MDS); and to correlate immunohistological variables with prognosis. METHODS--Bone marrow trephine biopsy specimens from 65 patients with MDS were immunophenotyped using a panel of antibodies. A minimum of 1000 cells from representative areas of marrow sections were counted at light microscopy. The association between immunohistological variables and prognosis was assessed. RESULTS--Compared with normal control marrows (n = 23) no major abnormalities of T cells (CD3), T cell subsets (CD4, CD8, CD25, TCR gamma/delta) or natural killer cells (CD56, CD57) were seen in the 65 patients. In high risk MDS (RAEB, RAEB-t) 19% of the cases showed increased numbers of B lymphocytes compared with none in the low risk group (RA, RARS) (p < 0.0090). Only percentages of B cells above 3% significantly correlated with poor survival (p = 0.0121 for CD19, p = 0.046 for CD22). CONCLUSIONS--The deviations in T lymphocyte counts seen in peripheral blood and in bone marrow aspirates could not be verified in bone marrow biopsy specimens.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baumann M. A., Milson T. J., Patrick C. W., Libnoch J. A., Keller R. H. Immunoregulatory abnormalities in myelodysplastic disorders. Am J Hematol. 1986 May;22(1):17–26. doi: 10.1002/ajh.2830220104. [DOI] [PubMed] [Google Scholar]
- Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189–199. [PubMed] [Google Scholar]
- Bynoe A. G., Scott C. S., Ford P., Roberts B. E. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol. 1983 May;54(1):97–102. doi: 10.1111/j.1365-2141.1983.tb02071.x. [DOI] [PubMed] [Google Scholar]
- Clark P., Normansell D. E., Innes D. J., Hess C. E. Lymphocyte subsets in normal bone marrow. Blood. 1986 Jun;67(6):1600–1606. [PubMed] [Google Scholar]
- Fenaux P., Jouet J. P., Zandecki M., Lai J. L., Simon M., Pollet J. P., Bauters F. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol. 1987 Jan;65(1):101–106. doi: 10.1111/j.1365-2141.1987.tb06142.x. [DOI] [PubMed] [Google Scholar]
- Hokland P., Kerndrup G., Griffin J. D., Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood. 1986 Apr;67(4):898–902. [PubMed] [Google Scholar]
- Kitagawa M., Kamiyama R., Takemura T., Kasuga T. Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(1):47–53. doi: 10.1007/BF02899064. [DOI] [PubMed] [Google Scholar]
- Takaku S., Takaku F. Natural killer cell activity and preleukaemia. Lancet. 1981 Nov 21;2(8256):1178–1178. doi: 10.1016/s0140-6736(81)90634-6. [DOI] [PubMed] [Google Scholar]
- Thaler J., Denz H., Gattringer C., Glassl H., Lechleitner M., Dietze O., Huber H. Diagnostic and prognostic value of immunohistological bone marrow examination: results in 212 patients with lymphoproliferative disorders. Blut. 1987 Apr;54(4):213–222. doi: 10.1007/BF00594196. [DOI] [PubMed] [Google Scholar]
- Willemze R., Fibbe W. E., Falkenburg J. H., Kluin-Nelemans J. C., Kluin P. M., Landegent J. E. Biology and treatment of myelodysplastic syndromes--developments in the past decade. Ann Hematol. 1993 Mar;66(3):107–115. doi: 10.1007/BF01697618. [DOI] [PubMed] [Google Scholar]